Introduction

The laboratory of Molecular Biology and Immunobiotechnology was founded in January 2004, having as its primary goal the exploitation of experimental findings that will be used for the development of novel diagnostic and therapeutic approaches in important fields of the biomedical science.

The laboratory of Molecular Biology and Immunobiotechnology focuses on:

• The development of new biotechnological drugs (production of recombinant biomolecules such as antigens, antibodies and peptides) of known and novel molecular targets, and
• Functional studies of molecular targets and biomolecules for the diagnosis and the therapeutic applications of several diseases

The main achievements of the laboratory include the:

• Production of rodent recombinant antibody fragments of monoclonal antibodies
• Production of human recombinant antibody fragments
• In vitro affinity maturation of human antibody fragments, and
• Production of recombinant proteins or peptides in heterologous expression systems (bacteria, yeast, protozoa)

The production of recombinant antibody fragments is a technology based on the construction of combinatorial cDNA libraries of Fab or scFv antibody fragments that are expressed on the surface of filamentous bacteriophages (phage display antibody libraries). These libraries allow the isolation of highly specific antibodies since they include the complete repertoire of antibodies expressed in B lymphocytes deriving from specific tissue. The laboratory of Molecular Biology and Immunobiotechnology is the pioneer lab in Greece where this technology has been applied and evolved with great success..

The current research activity of our lab focuses on:

α)  New research activity concerning the:

1. Cancer Immunotherapy and HER-2/neu. A combined approach of genes, proteins and drugs

2. Immunodiagnosis and Immunotherapy of Metabolic Disease, concerning Hepcidin. 

β)  On-going research activity that was previously developed in the Laboratory of Molecular Neurobiology and Immunology, during the last decade and concerns the:

3. Immunotherapy of Autoimmune Diseases - Myasthenia Gravis  

Introduction

The laboratory of Molecular Biology and Immunobiotechnology was founded in January 2004, having as its primary goal the exploitation of experimental findings that will be used for the development of novel diagnostic and therapeutic approaches in important fields of the biomedical science.

The laboratory of Molecular Biology and Immunobiotechnology focuses on:

• The development of new biotechnological drugs (production of recombinant biomolecules such as antigens, antibodies and peptides) of known and novel molecular targets, and
• Functional studies of molecular targets and biomolecules for the diagnosis and the therapeutic applications of several diseases

The main achievements of the laboratory include the:

• Production of rodent recombinant antibody fragments of monoclonal antibodies
• Production of human recombinant antibody fragments
• In vitro affinity maturation of human antibody fragments, and
• Production of recombinant proteins or peptides in heterologous expression systems (bacteria, yeast, protozoa)

The production of recombinant antibody fragments is a technology based on the construction of combinatorial cDNA libraries of Fab or scFv antibody fragments that are expressed on the surface of filamentous bacteriophages (phage display antibody libraries). These libraries allow the isolation of highly specific antibodies since they include the complete repertoire of antibodies expressed in B lymphocytes deriving from specific tissue. The laboratory of Molecular Biology and Immunobiotechnology is the pioneer lab in Greece where this technology has been applied and evolved with great success..

The current research activity of our lab focuses on:

α)  New research activity concerning the:

1. Cancer Immunotherapy and HER-2/neu. A combined approach of genes, proteins and drugs

2. Immunodiagnosis and Immunotherapy of Metabolic Disease, concerning Hepcidin. 

β)  On-going research activity that was previously developed in the Laboratory of Molecular Neurobiology and Immunology, during the last decade and concerns the:

3. Immunotherapy of Autoimmune Diseases - Myasthenia Gravis